|Home | About | Journals | Submit | Contact Us | Français|
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and malignant form of lung cancer with a poor prognosis for patients. The common sites of metastases are the liver, adrenal glands, bone and brain. LCNEC rarely metastasizes to the small intestine, ovaries, tonsils, mandible, vulva or spine. To the best of our knowledge, there have been no reports of leptomeningeal metastasis of LCNEC to date. The present case report describes an unusual case of leptomeningeal metastasis from pulmonary LCNEC alongside a review of the literature. Biopsies of pulmonary lesions and cervical lymph nodes confirmed the diagnosis of LCNEC in a 39-year-old male patient. At 2 months after chemotherapy, the patient began to experience hoarseness, epileptic seizures and blurred vision. Furthermore, the patient presented with radiating pain and numbness in his lower left limb. Imaging findings and cytological examination of cerebral spinal fluid supported the diagnosis of leptomeningeal metastasis. The patient's neurological symptoms were markedly alleviated following receipt of radiation and intrathecal chemotherapy. The patient survived for 4.9 months after diagnosis with leptomeningeal metastasis. To the best of our knowledge, the present case report is the first to describe leptomeningeal metastasis from pulmonary LCNEC confirmed by neuroimaging and cerebral spinal fluid cytology. It suggests that leptomeningeal metastasis does occur in this rare disease, and aggressive treatment may result in improved symptoms and possibly survival times.
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer that accounts for <1% of all primary lung malignancies (1). Since the biological behavior of LCNEC is similar to that of small cell lung cancer (SCLC), patients with LCNEC are often misdiagnosed and have an extremely poor prognosis (2). The 5-year survival rates for patients with LCNEC have been revealed to be significantly decreased compared with patients with other histological types of non-small cell lung cancer (NSCLC) (2,3).
The common sites of metastasis from LCNEC are the liver, adrenal glands, bone, and brain, with hematogenous metastasis being the primary cause of treatment failure. Until recently, the rare sites of metastases from LCNEC which have been reported include the ovaries, small intestine, mandible, tonsil, vulva and prostate (4–9). In addition, Tsimpas et al (10) reported a case of LCNEC metastasis in the cauda equina; however, the patient in this study did not receive a cerebrospinal fluid (CSF) test and was not able to be diagnosed with leptomeningeal metastasis. Paydas et al (11) reported a case of leptomeningeal metastasis from LCNEC, but no cytological examination had been performed and no line-enhancement imaging for the diagnosis of leptomeningeal metastasis was performed for the patient. To the best of our knowledge, the present case report is the first to describe leptomeningeal metastasis from pulmonary LCNEC confirmed by neuroimaging and CSF cytology. Thus, the present case report describes a rare case of leptomeningeal metastasis from LCNEC alongside a review of the literature.
A 39-year-old male was admitted to Norman Bethune First Hospital (Changchun, China) in April 2013 complaining of a cough and blood-stained sputum that lasted for 10 days. The patient had a 20-year history of drinking and smoking. A computed tomography (CT) scan of the chest revealed a mass in the right pulmonary hilum that was accompanied by an enlargement of the right supraclavicular and mediastinal lymph nodes. A transbronchial biopsy revealed that the tumor cells exhibited an unclear boundary, with infiltrative growth and numerous cells which were arranged as flaky, cord-like, adenoid or chrysanthemum-shaped clusters. The cells commonly presented with large volumes, polygonal shape, small cytoplasm, filamentous chromatin and intensely stained nuclei. Three to four abnormal mitotic events were observed in each high-power field. A wide range of tumor necrosis was visualized in the area of poor differentiation (Fig. 1A). Staining of the patient's tumor was positive for thyroid transcription factor-1 (TTF-1), cluster of differentiation 56 (CD56; also known as neural cell adhesion molecule), synaptophysin (Syn) (Fig. 1B-D) and p63 (interspersed), and negative for leucocyte common antigen. This supported the histological diagnosis of LCNEC. Pathological examination of the right supraclavicular lymph node indicated metastatic cancer invasion (Fig. 2A). This observation was confirmed by negative immunohistochemical staining for cytokeratin 5/6, and positive staining for TTF-1, CD56, Syn (Fig. 2B-D) and p63 (partial). This supported the histological diagnosis of a neuroendocrine carcinoma with a pulmonary origin. No other metastases were detected using an abdominal CT scan.
The patient had a partial response to six cycles of systemic chemotherapy with gemcitabine (2 g on day 1) and cisplatin (50 mg on days 1–3). The lesion decreased in size following two cycles of chemotherapy and the patient achieved partial disease control. No severe adverse effects were detected. At 2 months after the last chemotherapy cycle, the patient began to experience radiating pain and numbness in his left lower limb, hoarseness, epileptic seizures and blurred vision. Additionally, the patient suffered a seizure due to symptom aggravation. Conventional biochemical examinations including routine blood, urine, liver and kidney function tests were normal. Serum levels of tumor markers were 22.31 U/ml cancer antigen 153 (CA153), 1.16 ng/ml carcinoembryonic antigen (CEA), 14.6 ng/ml neuron-specific enolase (NSE) and 0.7 ng/ml CYFRA21-1. A CT scan of the brain revealed irregular low-density shadows from edema on the right parietal-occipital area (Fig. 3A). Magnetic resonance imaging (MRI) of the brain identified metastatic nodules in the inferior cortex, sulci and gyri and internal ventricles, and line-enhancements in the leptomeningeal mater (Fig. 3B-D). Gadolinium enhancement scans of the lumbar spine revealed flake-enhanced lesions in the T12 vertebra of the spine and nodular-enhanced lesions along the cauda equina nerve in the L3-4 space (Fig. 3E). A low signal nodule-like lesion along the cauda equina nerve was observed using T2-weighted imaging (T2WI; Fig. 3F). Results from a lumbar puncture revealed that the patient's CSF was colorless, intracranial pressure was 200 mmH2O, the protein level was 0.75 g/l and the glucose level was 3.35 mmol/l. Tumor cells were identified within the patient's CSF via liquid-based technology (ThinPrep TCT2000) combined with Papanicolaou staining (Fig. 4). Tumor marker levels in CSF were 1.00 U/ml CA153, 0.20 ng/ml CEA, 25.8 ng/ml NSE and 2.5 ng/ml CYFRA21-1. On the basis of these results, a diagnosis of leptomeningeal metastasis was made. The patient's Karnofsky performance status (KPS) (12) score was determined to be 40–50 points.
The patient's treatment regimen involved three-dimensional conformal radiotherapy with a 6 MV X-ray to the whole brain and thoracolumbar spinal canal, which consisted of a 40 Gy total radiation dose administered in 20 fractions over a 4-week period. Simultaneous administration of intrathecal chemotherapy using methotrexate (MTX, 15 mg) and dexamethasone (5 mg) was performed once a week. The first intrathecal chemotherapy began on the first day of radiotherapy. Three cycles of intrathecal chemotherapy and 14 days of radiotherapy (20 Gy in 10 fractions) markedly alleviated the patient's symptoms and his KPS score increased to 60 points. The patient declined further treatment for personal reasons and was discharged from the hospital. After 2 months, the patient began to experience headaches and numbness and succumbed due to disease progression. The patient's overall survival (OS) time was 11 months, and the patient had survived for 4.9 months from the time of diagnosis of leptomeningeal metastasis.
Written informed consent was obtained from the next of kin of the patient for publication of this case report and any accompanying images.
Leptomeningeal metastasis is a fatal complication of malignant cancers and occurs in 5% of patients diagnosed with solid tumors (13). This type of metastasis results from invasion of the subarachnoid space by the migratory tumor cells and dissemination through the CSF. Thus, patients usually have pleomorphic and multifocal neurological complaints due to disperse involvement of the central nervous system. Despite having an aggressive treatment regimen, the median OS time is between 2 and 3 months (13). Leptomeningeal metastasis often occurs in patients with melanoma, breast or lung cancer. Although lung cancer is one of the most common malignant solid tumors prone to invade the meninges, to the best of our knowledge, there has been no report concerning leptomeningeal metastasis from pulmonary LCNEC. To the best of our knowledge, the present case report documents the first cytologically confirmed case of leptomeningeal involvement from LCNEC.
In 1991, Travis et al (14) first described the histological characteristics of LCNEC, which included large cells with abundant cytoplasm, a high mitotic rate, extensive necrosis and a neuroendocrine growth pattern. In 2001, the World Health Organization suggested that, in order to confirm the neuroendocrine origin of the tumor cells and thereby diagnose LCNEC, a neuroendocrine morphology and positive immunohistochemical staining for at least one neuroendocrine-specific marker, e.g. chromogranin, CD56 or Syn, must be present (15). In the present case report, histopathological examination of the patient's primary lung tumor and cervical lymph nodes combined with immunohistochemistry confirmed the diagnosis of LCNEC.
An MRI examination is a critical auxiliary diagnosis for leptomeningeal metastasis (13). The major imaging features include dot- and line-enhancements in the leptomeningeal mater, metastatic nodules in the sulci and gyri, inferior cortex, internal ventricles and seeding nodules along the cauda equina nerve (13). In the present case report, the patient exhibited all of the clinical imaging manifestations mentioned above that conformed to the characteristics of implantation metastases. In particular, line-enhancements in the sulci and gyri and implanted metastatic nodules along the cauda equina nerve are considered specific imaging features for leptomeningeal metastasis, which may be used as a diagnostic tool (14).
CSF cytological analysis provides the optimum assessment of leptomeningeal metastasis (13). In this case, the tumor cells exhibited evident characteristics of malignancy that included large cellular volumes, pleomorphism, markedly increased nuclear-to-cytoplasmic ratio and markedly stained chromatin.
There are a limited number of reports describing the treatment regimens for patients with LCNEC. Several studies have demonstrated that the response rate of LCNEC to cisplatin-based chemotherapy was similar to that of small cell carcinoma (16). In 2013, a multicenter prospective study reported the median progression-free survival and OS time for 42 patients with advanced stage LCNEC were 5.2 months and 7.7 months respectively, following cisplatin-irinotecan chemotherapy (17).
Patients with leptomeningeal metastasis, which is a fatal complication of malignant tumor, have a very poor prognosis. The main objective of leptomeningeal metastasis treatment is to alleviate symptoms of the nervous system, improve quality of life and prolong the survival time of the patient (13). Owing to the direct exposure of the central nervous system to cancer cells, a whole central nervous system therapy using intrathecal chemotherapy alone or in combination with local radiotherapy should be performed (13). MTX remains the most widely used and clinically effective intrathecal chemotherapeutic drug used to treat leptomeningeal metastasis from solid tumors (13). Currently, an intrathecal injection of 10–15 mg MTX twice weekly is more commonly used in the initial treatment (13). Radiotherapy on bulky disease observed on MRI or sites of symptomatic disease eliminates locally aggregated tumor cells and re-establishes the normal CSF circulation to improve the efficacy, as well as decrease the toxicity of intrathecal chemotherapy. In addition, metastatic lesions in the brain parenchyma may also be effectively treated simultaneously (13). The regimen of whole brain radiotherapy commonly consists of a total radiation dose of 30 Gy in 10 fractions for 2 weeks (13). In the present case, the patient received simultaneous intrathecal chemotherapy with radiotherapy. To reduce neurotoxicity, the single radiotherapy dosage was set at 2 Gy and the density of the regimen of intrathecal MTX was reduced to once per week. The treatment was well tolerated by the patient and the symptoms were alleviated rapidly. There was no severe adverse reaction. However, the patient failed to complete all treatments owing to personal reasons and succumbed to disease progression.
Currently, there is no standard therapy regimen for leptomeningeal metastasis from solid tumors. Intrathecal chemotherapy and radiotherapy are valuable treatment approaches, but an optimal combination of distinct treatments has not been extensively studied. The male patient in the present case report presented multiple adverse prognostic factors including a low KPS score as well as severe and pleomorphism nerve dysfunction. Previous studies indicated that intrathecal chemotherapy does not improve OS times in solid tumors (18–20) and National Comprehensive Cancer Network (NCCN) guidelines suggest that radiation therapy alone may produce a positive effect with less toxicity. However, studies have demonstrated that radiation therapy alone only alleviated symptoms of the nervous system and did not prolong patient OS times (21,22).
NCCN guidelines suggest the use of simultaneous intrathecal chemotherapy and radiation in leptomeningeal metastasis, but this combination treatment has not been extensively studied. Therefore, this approach was adopted to treat leptomeningeal metastasis in patients with adverse prognostic factors. Untreated patients with leptomeningeal metastasis have a median survival time of 4–6 weeks; this survival time may be prolonged to 2–3 months in patients with NSCLC from leptomeningeal metastasis by using effective treatments (13). In the present case report, the patient did not suffer obvious toxic effects and survived for 4.9 months from the time of diagnosis of leptomeningeal metastasis. This time was longer than the median survival time previously reported, suggesting a benefit of administration of simultaneous treatments to alleviate neurological symptoms and extend survival times.
In conclusion, pulmonary LCNEC with leptomeningeal metastasis is a rare disease that is associated with poor prognosis. Nevertheless, the present case report and review of the literature suggest that doctors should realize the potential of leptomeningeal metastasis from pulmonary LCNEC, and aggressive treatment may result in improved symptoms and possibly survival.
The authors wish to thank Dr Yongxiang Wang for her expert technical assistance with cytological analysis of cerebrospinal fluid.